Besides increased exposure potentially helping enr
Post# of 148175
(Total Views: 540)
Posted On: 04/29/2020 9:33:43 PM
Besides increased exposure potentially helping enrollment in other indications, I do not see COVID expediting HIV combo/mono or cancer trials. Good clinical results in each indication's specific clinical trial is likely the only thing speeding up any approval.
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼